disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Nio, XPeng stocks surge after EV delivery dataShares of China-based electric-vehicle makers surged Monday, after they reported June deliveries that showed big jumps from May.
Leggi di più »
Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and moreThese are the stocks posting the largest moves in premarket trading.
Leggi di più »